Doryx Mpc

Rocky Mountain Spotted Fever, Acinetobacter Infections, Ureaplasma Infections + 61 more

Treatment

93 FDA approvals

20 Active Studies for Doryx Mpc

Treatment for

Rocky Mountain Spotted Fever

What is Doryx Mpc

Doxycycline

The Generic name of this drug

Treatment Summary

Doxycycline is an antibiotic used to treat a variety of bacterial infections. It is derived from oxytetracycline and is considered a safer version of the first-generation tetracyclines. Doxycycline is usually prescribed after testing the bacteria to determine if it is sensitive to the drug.

Vibramycin Hyclate

is the brand name

image of different drug pills on a surface

Doryx Mpc Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Vibramycin Hyclate

Doxycycline

1967

728

Approved as Treatment by the FDA

Doxycycline, otherwise known as Vibramycin Hyclate, is approved by the FDA for 93 uses such as Severe Acne and Streptococcus Pneumoniae Infections .

Severe Acne

Streptococcus Pneumoniae Infections

Intestinal Amebiasis

Chlamydia Infections

Primary Syphilis

Anal chlamydia infection

Upper Respiratory Tract Infection

Clostridium difficile Infection

Genus Chlamydia

Communicable Diseases

Actinomycosis

Secondary Syphilis

Rickettsialpox

Klebsiella Infections

Cholera (Disorder)

Campylobacter Infections

Mycoplasma Pneumoniae

Inclusion conjunctivitis

Necrotizing ulcerative gingivostomatitis

Chlamydia Infections

Urethritis

Ureaplasma urethritis

Chlamydial Urethritis

Listeria infection

Urinary Tract Infections

Bacteriological Techniques

Staphylococcus (S.) Aureus Infection

Relapsing fever caused by Borrelia recurrentis

Campylobacter Infection

Tick-borne fever

Plasmodium Infections

Skin Infections

Chlamydia trachomatis

Typhus, Endemic Flea-Borne

Communicable Diseases

Chlamydial cervicitis

Haemophilus Influenzae Infections

Calymmatobacterium granulomatis

Lymphogranuloma Venereum

Dysentery, Bacillary

Fever

Gonorrhea

Bartonella Infections

Acne Vulgaris

Q Fever

Acinetobacter Infections

Ureaplasma Infections

Communicable Diseases

Uterine Cervicitis

Tularemia

Typhus infections

Epididymo-orchitis gonococcal

Trachoma

Neisseria Gonorrhoeae Infection

Rocky Mountain Spotted Fever

Bartonella bacilliformis infections

Malaria

Bacterial Infection caused by Enterobacter aerogenes

Relapsing Fever

Yaws

Chancroid

Amebic colitis

Brucellosis

Used to treat Brucellosis in combination with Streptomycin

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

Plague

Chlamydia trachomatis

Cat-Scratch Disease

Shigella Infection

inhaled anthrax caused by Bacillus anthracis

Pneumococcal Infections

Clostridium Infections

Common Cold

Brucellosis

Used to treat Brucellosis in combination with Streptomycin

Trachoma

Plague

Urethritis

Acinetobacter Infections

Yersinia pestis

Psittacosis

Chlamydia psitacci infection

Ureaplasma Infections

Infection Due to Escherichia Coli

Trachoma inclusion conjunctivitis

Listeriosis

Yaws

Relapsing Fever

Vibrio Cholerae Infection

Disease

Haemophilus ducreyi infection

Tularemia

prophylaxis of Malaria

Respiratory Tract Infections

Granuloma Inguinale

Effectiveness

How Doryx Mpc Affects Patients

Doxycycline is a type of medicine that prevents bacteria from growing. It is effective against both gram-positive and gram-negative bacteria. Doxycycline is easily absorbed by cells and can penetrate inside the body. It can also fight certain parasites and inflammation. Studies have shown that doxycycline can help with skin conditions such as bullous dermatoses and rosacea.

How Doryx Mpc works in the body

Doxycycline works to stop bacteria from making proteins, which are vital for their survival. It does this by blocking an amino acid from attaching to the ribosome, which is the part of the cell that produces proteins. By preventing this attachment, doxycycline stops the production of essential proteins, ultimately leading to the death of the bacterial cell. Furthermore, doxycycline also reduces inflammation by preventing calcium-dependent microtubular assembly and by inhibiting the production of nitric oxide, an inflammatory signaling molecule.

When to interrupt dosage

The quantity of Doryx Mpc is contingent upon the indicated affliction, including Urethritis, Chlamydia trachomatis and Respiratory Tract Infections. The amount also shifts as per the delivery technique (e.g. Capsule or Syrup - Oral) referenced in the table beneath.

Condition

Dosage

Administration

Urinary Tract Infections

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension, For suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Kit, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Gel - Oral, Suspension - Oral

Primary Syphilis

inhaled anthrax caused by Bacillus anthracis

Psittacosis

Brucellosis

Bacteriological Techniques

Relapsing Fever

Actinomycosis

prophylaxis of Malaria

Mycoplasma Pneumoniae

Chlamydia Infections

Ureaplasma Infections

Q Fever

Epididymo-orchitis gonococcal

Rosacea

Listeriosis

Necrotizing ulcerative gingivostomatitis

Dysentery, Bacillary

Pneumococcal Infections

Klebsiella Infections

Warnings

Doryx Mpc has three restrictions. It should not be consumed when a person has any of the circumstances in the following table.

Doryx Mpc Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Doxycycline may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Doxycycline may interact with Pulse Frequency

There are 20 known major drug interactions with Doryx Mpc.

Common Doryx Mpc Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Doxycycline.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Doxycycline.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Doxycycline.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Doxycycline.

Amdinocillin

Major

The therapeutic efficacy of Amdinocillin can be decreased when used in combination with Doxycycline.

Doryx Mpc Toxicity & Overdose Risk

The toxic dose of doxycycline for rats has been found to be 2000 mg/kg, 1870 mg/kg in mice, and 500 mg/kg in dogs. If someone takes too much of this drug, it should be stopped immediately and supportive care should be given. Dialysis won't help to reduce the amount of drug in the bloodstream.

Doryx Mpc Novel Uses: Which Conditions Have a Clinical Trial Featuring Doryx Mpc?

34 active studies are currently in progress to investigate the effectiveness of Doryx Mpc in treating Haemophilus Influenzae Infections, Respiratory Tract Infections and Amebic Colitis.

Condition

Clinical Trials

Trial Phases

Plague

0 Actively Recruiting

Plague

0 Actively Recruiting

Epididymo-orchitis gonococcal

0 Actively Recruiting

Lymphogranuloma Venereum

0 Actively Recruiting

Gonorrhea

0 Actively Recruiting

Urinary Tract Infections

9 Actively Recruiting

Not Applicable, Phase 4, Early Phase 1

Chlamydia trachomatis

0 Actively Recruiting

Pneumococcal Infections

0 Actively Recruiting

Urethritis

0 Actively Recruiting

Typhus, Endemic Flea-Borne

0 Actively Recruiting

Clostridium difficile Infection

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Chlamydia Infections

0 Actively Recruiting

inhaled anthrax caused by Bacillus anthracis

0 Actively Recruiting

Calymmatobacterium granulomatis

0 Actively Recruiting

Haemophilus Influenzae Infections

0 Actively Recruiting

Chancroid

0 Actively Recruiting

Klebsiella Infections

0 Actively Recruiting

Rosacea

2 Actively Recruiting

Early Phase 1, Phase 2

Rocky Mountain Spotted Fever

0 Actively Recruiting

Patient Q&A Section about doryx mpc

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is doryx MPC used for?

"This medication is an antibiotic that's used to treat a variety of bacterial infections, including acne. It's also used to prevent malaria."

Answered by AI

Is doryx the same as doxycycline?

"Doryx is a brand name for the antibiotic drug doxycycline, which is used to treat infections caused by bacteria. It may also be used to reduce inflammation in some autoimmune diseases."

Answered by AI

What are the side effects of doryx?

"The following are some possible side effects: feeling nauseous, vomiting, having an upset stomach, loss of appetite, mild diarrhea, skin rash or itching, darkened skin color, or vaginal itching or discharge."

Answered by AI

How long should you take doryx?

"This medication is to be taken 1 to 2 days before travel, or as directed by a doctor. Continue to take the medication daily while in a malarious area. Once returning home, it is advised to keep taking the medication for 4 more weeks."

Answered by AI

Clinical Trials for Doryx Mpc

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17

All Sexes

Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4

Waitlist Available

New This Month

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Have you considered Doryx Mpc clinical trials?

We made a collection of clinical trials featuring Doryx Mpc, we think they might fit your search criteria.

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+

All Sexes

Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available

Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD